Luca Massacesi

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Laura J. Balcer, Steven Galetta et al. · The Lancet Neurology · 2017 · 271 citations · Full text

Medicine, Neurology, Ophthalmology +6

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

Paolo A. Muraro, Marcelo C. Pasquini, Harold Atkins et al. · JAMA Neurology · 2017 · 269 citations · Full text

Medicine, Neurology, Cell Therapy +14

Autologous hematopoietic stem cell transplantation in multiple sclerosis

Maria Pia Sormani, Francesca Gualandi, Albert Saiz et al. · Neurology · 2015 · 247 citations

Medicine, Immunology, Neurology +17

Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies

Pietro Maggi, Martina Absinta, Matteo Grammatico et al. · Annals of Neurology · 2018 · 245 citations · Full text

Medicine, Neurology, Neuroscience +17